Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Selenomethionine · 1 trial · 1 indication
The AEs will be summarized and classified by body system and by treatment group. The type, incidence, severity, and causality of each AE, the duration of the event, and any required treatment interventions will be tabulated.
Dose escalation for this pilot study will be conducted using a CRM in which the probability of exceeding a blood selenium concentration of 45 µM on Day 14 is being modeled. Prior probabilities of exceeding a blood selenium concentration of 45 µM on Day 14 were estimated based on preclinical and preliminary data from the initial trial. A one parameter logistic model with intercept set at 3 and an initial value of 1 for the slope will be used to estimate the dose-concentration relationship through sequential recursive Bayesian assessment. The target probability of exceeding 45 µM is ≤20%.
| Arm | Type | Description |
|---|---|---|
| Study Treatment | EXPERIMENTAL | During the Dose-Escalation Part 1, patients will receive SLM twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity. During the Expansion Part 2, patients will be treated at the maximum tolerated dose (MTD) of SLM determined as 4000 mcg SLM. SLM will be given orally twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity. During the Pilot Phase, dosing will begin at dose level 3 (4000, 5000, or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days. Each cohort will enroll 2 evaluable patients. |
| Name | Type | Description |
|---|---|---|
| Selenomethionine (SLM) | DRUG | SLM administrated orally twice daily for 14 days followed by SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert |
| Axitinib | DRUG | Following SLM administrated orally twice daily for 14 days, SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert |
Inclusion Criteria: Each patient must meet all of the following criteria to be enrolled in this study: * Histologically and radiologically confirmed advanced metastatic CCRCC in patients who have had at least one prior systemic therapy, which can include axitinib for the dose escalation part. In t...
Selenomethionine is an investigational small molecule being studied for the treatment of Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC). It is being evaluated in combination with axitinib in a Phase 1 clinical trial. The drug is not yet approved and remains in clinical development.
Selenomethionine is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. The company is conducting clinical research on this investigational small molecule for the treatment of Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC).
Selenomethionine is in Phase 1 clinical development. It is an investigational drug being studied for Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC). The drug is not FDA approved and is still undergoing clinical trials to evaluate its safety and efficacy.
Selenomethionine has one completed clinical trial, NCT02535533, titled 'SLM + Axitinib for Clear Cell RCC'. This Phase 1 study enrolled 45 participants with Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) in the United States. The trial was uncontrolled and not randomized or double-blinded.
Yes, Selenomethionine is referred to as SLM in clinical trial documentation. The Phase 1 trial NCT02535533 is titled 'SLM + Axitinib for Clear Cell RCC', confirming that SLM is the abbreviation used for Selenomethionine in this research context.